Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 2106442

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 2106442

Live Biotherapeutics Global Market Report 2026

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4490
PDF & Excel (Site License)
USD 6490
PDF & Excel (Enterprise License)
USD 8490

Add to Cart

Live biotherapeutics are pharmaceutical biological products composed of living microorganisms, including bacteria and yeasts, that are intended to prevent, manage, or treat human diseases. These therapies exert their effects by interacting with the body's microbiome or physiological processes to deliver therapeutic benefits and are manufactured under stringent pharmaceutical standards to ensure their safety, effectiveness, and quality.

The primary product types of live biotherapeutics include single-strain live biotherapeutics, multi-strain live biotherapeutics, genetically engineered live biotherapeutics, fecal microbiota-based therapeutics, and bacterial consortia therapeutics. Single-strain live biotherapeutics refer to therapeutic products containing a single live microorganism strain intended to prevent, manage, or treat specific diseases. These products are developed using microorganism types including bacteria-based therapeutics, yeast-based therapeutics, viral or bacteriophage-based therapeutics, and mixed microbial therapeutics, and are administered through oral, rectal, and other routes of administration. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and the key applications include gastrointestinal disorders, infectious diseases, oncology supportive care, metabolic disorders, autoimmune and inflammatory diseases, neurological disorders, dermatological conditions, and respiratory disorders.

Tariffs are influencing the live biotherapeutics market by increasing the cost of imported fermentation systems, bioprocessing equipment, and temperature-controlled logistics components required for manufacturing and distribution. This is creating supply chain bottlenecks and raising production costs, particularly affecting fecal microbiota-based therapies and genetically engineered live biotherapeutics that rely on specialized infrastructure. Regions such as North America and Europe, which depend on Asia-Pacific manufacturing hubs for key raw materials and equipment, are experiencing slower commercialization and delayed scaling of advanced therapies. However, tariffs are also encouraging domestic production capabilities, regional supply chain diversification, and increased investment in localized biomanufacturing ecosystems, which may strengthen long-term resilience and reduce dependency on global suppliers.

The live biotherapeutics market size has grown rapidly in recent years. It will grow from $92.31 billion in 2025 to $105.62 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing prevalence of gastrointestinal and metabolic disorders, rising utilization of probiotics in clinical nutrition practices, early expansion of microbiome research initiatives, growing awareness of gut health benefits among consumers, and limited availability of targeted biological treatment options.

The live biotherapeutics market size is expected to see rapid growth in the next few years. It will grow to $182.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period is driven by rapid progress in precision microbiome engineering technologies, rising regulatory approvals for live biotherapeutic products, increasing investments in microbiome-focused drug development pipelines, broader adoption of personalized medicine approaches, and growing demand for targeted therapies that avoid antibiotic use. Key trends in the forecast period include greater integration of microbiome-based treatments into hospital protocols, rising adoption of patient-specific microbiome modulation therapies, increasing regulatory standardization and harmonization for live biotherapeutic products, expansion of clinical trials focused on next-generation engineered microbial therapies, and growing demand for non-antibiotic therapeutic alternatives in chronic disease treatment.

The rising prevalence of gastrointestinal disorders and inflammatory bowel diseases (IBD) is expected to propel the growth of the live biotherapeutics market going forward. Gastrointestinal disorders and inflammatory bowel diseases are chronic digestive system conditions that cause inflammation, immune dysfunction, abdominal pain, diarrhea, and damage to the gastrointestinal tract. The increasing prevalence of gastrointestinal disorders and inflammatory bowel diseases is primarily driven by unhealthy dietary habits and increased consumption of processed foods, which disrupt gut microbiota and contribute to chronic intestinal inflammation. Live biotherapeutics assist in the management of gastrointestinal diseases by restoring microbial balance, improving gut health, reducing intestinal inflammation, and offering targeted microbiome-based therapeutic solutions for chronic digestive disorders. For instance, in February 2025, according to Crohn's & Colitis Australia, an Australia-based national organization, the projected prevalence of inflammatory bowel disease (IBD) in Australia is expected to increase from 20,511,881 cases in 2023 to 23,067,771 cases by 2030. Therefore, the rising prevalence of gastrointestinal disorders and inflammatory bowel diseases is driving the growth of the live biotherapeutics market.

Leading companies operating in the live biotherapeutics market are focusing on developing advanced solutions, such as integrated multi-omics microbiome platforms, to enhance microbiome research, improve therapeutic discovery, and accelerate the development of next-generation live biotherapeutic products. Integrated multi-omics microbiome platforms refer to advanced scientific systems that combine microbiome, metabolomics, bioinformatics, and AI-driven analytics to generate comprehensive biological insights for therapeutic development. For example, in November 2024, Cmbio, a Denmark-based microbiome and metabolomics science company, launched a unified global brand integrating Clinical Microbiomics, CosmosID, MS-Omics, DNASense, and Microba's Research Services Unit under one platform. The new platform combines GxP-certified laboratory services, AI-powered bioinformatics, and scalable multi-omics technologies to support microbiome innovation across pharmaceutical, biotechnology, and healthcare sectors, enabling faster and more standardized microbiome-based therapeutic research and development.

In October 2023, Kanvas Biosciences, a US-based microbiome therapeutics company, acquired key assets from Federation Bio for an undisclosed amount. This acquisition enhances Kanvas Biosciences' capabilities in developing and manufacturing microbiome-based therapeutics and live biotherapeutic products by expanding its bioprocessing infrastructure and strengthening its microbiome platform technologies. Federation Bio is a US-based company specializing in the development of microbiome therapeutics and live biotherapeutic products.

Major companies operating in the live biotherapeutics market are Ferring Pharmaceuticals SA, Rebiotix Inc., Seres Therapeutics Inc., MaaT Pharma SA, Vedanta Biosciences Inc., Infant Bacterial Therapeutics AB, EnteroBiotix Limited, AOB Pharma Inc., BiomX Inc., Microbiotica Limited, Azitra Inc., MRM Health NV, BiomeBank Pty Ltd, Siolta Therapeutics Inc., Servatus Biopharmaceuticals Pty Ltd, Scioto Biosciences Inc.

North America was the dominant region in the live biotherapeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in live biotherapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the live biotherapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The live biotherapeutics market consists of sales of spore-forming microbial therapeutics, yeast-derived live biotherapeutics, probiotic therapeutics, microbiome restoration therapies, and synthetic microbial therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The live biotherapeutics market research report is one of a series of new reports from The Business Research Company that provides live biotherapeutics market statistics, including live biotherapeutics industry global market size, regional shares, competitors with a live biotherapeutics market share, detailed live biotherapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the live biotherapeutics industry. This live biotherapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Live Biotherapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses live biotherapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for live biotherapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The live biotherapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product Type: Single Strain Live Biotherapeutics; Multi Strain Live Biotherapeutics; Genetically Engineered Live Biotherapeutics; Fecal Microbiota Based Therapeutics; Bacterial Consortia Therapeutics
  • 2) By Microorganism Type: Bacteria Based Therapeutics; Yeast Based Therapeutics; Viral Or Bacteriophage Based Therapeutics; Mixed Microbial Therapeutics
  • 3) By Route Of Administration: Oral; Rectal; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 5) By Application: Gastrointestinal Disorders; Infectious Diseases; Oncology Supportive Care; Metabolic Disorders; Autoimmune And Inflammatory Diseases; Neurological Disorders; Dermatological Conditions; Respiratory Disorders
  • Subsegments:
  • 1) By Single Strain Live Biotherapeutics: Lactobacillus Based Therapeutics; Bifidobacterium Based Therapeutics; Clostridium Based Therapeutics; Saccharomyces Based Therapeutics; Escherichia Coli Based Therapeutics; Bacillus Based Therapeutics
  • 2) By Multi Strain Live Biotherapeutics: Lactobacillus And Bifidobacterium Combinations; Gut Microbiota Restoration Consortia; Anaerobic Bacterial Mixtures; Synbiotic Multi Strain Therapeutics; Immunomodulatory Microbial Combinations; Disease Specific Microbial Cocktails
  • 3) By Genetically Engineered Live Biotherapeutics: Synthetic Biology Based Therapeutics; Clustered Regularly Interspaced Short Palindromic Repeats Engineered Microbial Therapeutics; Metabolite Producing Engineered Bacteria; Targeted Drug Delivery Microorganisms; Gene Editing Enabled Microbial Therapies; Recombinant Probiotic Therapeutics
  • 4) By Fecal Microbiota Based Therapeutics: Fecal Microbiota Transplantation Products; Oral Fecal Microbiota Transplantation Capsules; Donor Derived Microbial Suspensions; Standardized Stool Derived Therapeutics; Rectal Microbiota Therapeutics; Lyophilized Fecal Microbiota Products
  • 5) By Bacterial Consortia Therapeutics: Defined Bacterial Consortium Therapeutics; Rationally Designed Microbial Communities; Commensal Bacteria Therapeutics; Spore Forming Bacterial Consortia; Precision Microbiome Consortia; Next Generation Microbial Ecosystem Therapeutics
  • Companies Mentioned: Ferring Pharmaceuticals SA; Rebiotix Inc.; Seres Therapeutics Inc.; MaaT Pharma SA; Vedanta Biosciences Inc.; Infant Bacterial Therapeutics AB; EnteroBiotix Limited; AOB Pharma Inc.; BiomX Inc.; Microbiotica Limited; Azitra Inc.; MRM Health NV; BiomeBank Pty Ltd; Siolta Therapeutics Inc.; Servatus Biopharmaceuticals Pty Ltd; Scioto Biosciences Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH3MLBIO03_G26Q2

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Live Biotherapeutics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Live Biotherapeutics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Live Biotherapeutics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Live Biotherapeutics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Autonomous Systems, Robotics & Smart Mobility
  • 4.2. Major Trends
    • 4.2.1 Rising Integration Of Microbiome Based Therapeutics In Hospital Clinical Protocols
    • 4.2.2 Increasing Adoption Of Personalized Microbiome Modulation Therapies
    • 4.2.3 Growing Standardization And Regulatory Harmonization Of Live Biotherapeutic Products
    • 4.2.4 Expanding Clinical Trials For Next Generation Engineered Microbial Therapies
    • 4.2.5 Increasing Demand For Non Antibiotic Treatment Alternatives In Chronic Disease Management

5. Live Biotherapeutics Market Analysis Of End Use Industries

  • 5.1 Hospital Laboratories
  • 5.2 Specialty Clinics
  • 5.3 Research Institutes
  • 5.4 Pharmaceutical Companies
  • 5.5 Biotechnology Companies

6. Live Biotherapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Live Biotherapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Live Biotherapeutics PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Live Biotherapeutics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Live Biotherapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Live Biotherapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Live Biotherapeutics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Live Biotherapeutics Market Segmentation

  • 9.1. Global Live Biotherapeutics Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Single Strain Live Biotherapeutics, Multi Strain Live Biotherapeutics, Genetically Engineered Live Biotherapeutics, Fecal Microbiota Based Therapeutics, Bacterial Consortia Therapeutics
  • 9.2. Global Live Biotherapeutics Market, Segmentation By Microorganism Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Bacteria Based Therapeutics, Yeast Based Therapeutics, Viral Or Bacteriophage Based Therapeutics, Mixed Microbial Therapeutics
  • 9.3. Global Live Biotherapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oral, Rectal, Other Routes Of Administration
  • 9.4. Global Live Biotherapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • 9.5. Global Live Biotherapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Gastrointestinal Disorders, Infectious Diseases, Oncology Supportive Care, Metabolic Disorders, Autoimmune And Inflammatory Diseases, Neurological Disorders, Dermatological Conditions, Respiratory Disorders
  • 9.6. Global Live Biotherapeutics Market, Sub-Segmentation Of Single Strain Live Biotherapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lactobacillus Based Therapeutics, Bifidobacterium Based Therapeutics, Clostridium Based Therapeutics, Saccharomyces Based Therapeutics, Escherichia Coli Based Therapeutics, Bacillus Based Therapeutics
  • 9.7. Global Live Biotherapeutics Market, Sub-Segmentation Of Multi Strain Live Biotherapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lactobacillus And Bifidobacterium Combinations, Gut Microbiota Restoration Consortia, Anaerobic Bacterial Mixtures, Synbiotic Multi Strain Therapeutics, Immunomodulatory Microbial Combinations, Disease Specific Microbial Cocktails
  • 9.8. Global Live Biotherapeutics Market, Sub-Segmentation Of Genetically Engineered Live Biotherapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Synthetic Biology Based Therapeutics, CRISPR Engineered Microbial Therapeutics, Metabolite Producing Engineered Bacteria, Targeted Drug Delivery Microorganisms, Gene Editing Enabled Microbial Therapies, Recombinant Probiotic Therapeutics
  • 9.9. Global Live Biotherapeutics Market, Sub-Segmentation Of Fecal Microbiota Based Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fecal Microbiota Transplantation Products, Oral Fecal Microbiota Transplantation Capsules, Donor Derived Microbial Suspensions, Standardized Stool Derived Therapeutics, Rectal Microbiota Therapeutics, Lyophilized Fecal Microbiota Products
  • 9.10. Global Live Biotherapeutics Market, Sub-Segmentation Of Bacterial Consortia Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Defined Bacterial Consortium Therapeutics, Rationally Designed Microbial Communities, Commensal Bacteria Therapeutics, Spore Forming Bacterial Consortia, Precision Microbiome Consortia, Next Generation Microbial Ecosystem Therapeutics

10. Live Biotherapeutics Market Regional And Country Analysis

  • 10.1. Global Live Biotherapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Live Biotherapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Live Biotherapeutics Market

  • 11.1. Asia-Pacific Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Live Biotherapeutics Market

  • 12.1. China Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Live Biotherapeutics Market

  • 13.1. India Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Live Biotherapeutics Market

  • 14.1. Japan Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Live Biotherapeutics Market

  • 15.1. Australia Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Live Biotherapeutics Market

  • 16.1. Indonesia Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Live Biotherapeutics Market

  • 17.1. South Korea Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Live Biotherapeutics Market

  • 18.1. Taiwan Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Live Biotherapeutics Market

  • 19.1. South East Asia Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Live Biotherapeutics Market

  • 20.1. Western Europe Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Live Biotherapeutics Market

  • 21.1. UK Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Live Biotherapeutics Market

  • 22.1. Germany Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Live Biotherapeutics Market

  • 23.1. France Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Live Biotherapeutics Market

  • 24.1. Italy Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Live Biotherapeutics Market

  • 25.1. Spain Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Live Biotherapeutics Market

  • 26.1. Eastern Europe Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Live Biotherapeutics Market

  • 27.1. Russia Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Live Biotherapeutics Market

  • 28.1. North America Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Live Biotherapeutics Market

  • 29.1. USA Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Live Biotherapeutics Market

  • 30.1. Canada Live Biotherapeutics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Live Biotherapeutics Market

  • 31.1. South America Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Live Biotherapeutics Market

  • 32.1. Brazil Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Live Biotherapeutics Market

  • 33.1. Middle East Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Live Biotherapeutics Market

  • 34.1. Africa Live Biotherapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Live Biotherapeutics Market, Segmentation By Product Type, Segmentation By Microorganism Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Live Biotherapeutics Market Regulatory and Investment Landscape

36. Live Biotherapeutics Market Competitive Landscape And Company Profiles

  • 36.1. Live Biotherapeutics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Live Biotherapeutics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Live Biotherapeutics Market Company Profiles
    • 36.3.1. Ferring Pharmaceuticals SA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Rebiotix Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Seres Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. MaaT Pharma SA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Vedanta Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Live Biotherapeutics Market Other Major And Innovative Companies

  • Infant Bacterial Therapeutics AB, EnteroBiotix Limited, AOB Pharma Inc., BiomX Inc., Microbiotica Limited, Azitra Inc., MRM Health NV, BiomeBank Pty Ltd, Siolta Therapeutics Inc., Servatus Biopharmaceuticals Pty Ltd, Scioto Biosciences Inc.

38. Global Live Biotherapeutics Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Live Biotherapeutics Market

41. Live Biotherapeutics Market High Potential Countries, Segments and Strategies

  • 41.1 Live Biotherapeutics Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Live Biotherapeutics Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Live Biotherapeutics Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!